Navigation Links
InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
Date:3/6/2009

- Company Receives Allowance of Patent Claims in the U.S. and in India -

- InNexus Biotechnology CEO Highlighted in Nature Biotechnology -

BRITISH COLUMBIA, Canada, March 6 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces that it has received a notice of allowance on patent claims in the United States (Serial No. 11/119,404) and a patent grant in India (National Phase Application No. 2424/CHENP/2005) further expanding its protection of InNexus' DXL(TM) technology.

Speaking on today's announcement, InNexus Chairman and CEO, Jeff Morhet said, "DXL(TM) antibodies that penetrate directly into cells, is an exciting achievement for InNexus and our industry. As we've continued to expand our patent portfolio and discover new technologies to develop products, the team has aggressively pursued patent protection for our novel inventions. Patents are the currency of our industry and a driver for enhanced value for our shareholders and potential use of these cell penetrating DXL(TM) antibodies represents another frontier for the use of antibodies for therapeutic and diagnostic applications."

Dr. Thomas Kindt, Chief Scientific Officer of InNexus said, "The claims in these patents are directed toward the addition of membrane transport sequences to DXL antibodies, which facilitate penetration of DXL(TM) antibodies into cancer cells. The ability to direct our DXL(TM) antibodies to intracellular targets by the addition of a membrane transport sequence, imparts great therapeutic potential in a number of applications. The patents and applications also include coverage for new molecules and products of InNexus. We like to say We Build Better Antibodies and today, we demonstrated that once again."

InNexus also announced that Jeff Morhet, Chairman and CEO, was recently highlighted and quoted in an article titled "JAMA study casts cloud over biologic safety" in the January 2009 issue of Nature Biotechnology. A copy of the article can be downloaded at: http://www.nature.com/nbt/journal/v27/n1/pdf/nbt0109-11.pdf. Nature Biotechnology is a widely read academic journal published by Nature Publishing Group, a division of Macmillan Publishers Ltd., covering the science and business of biotechnology.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
2. InNexus Completes Previously Announced Private Placement
3. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
4. InNexus Biotechnology Receives Patent Grants in Europe
5. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
6. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
7. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
8. InNexus Biotechnology Strengthens Patent Team With New Leadership
9. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
10. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
11. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):